Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA

Executive Summary

Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.

You may also be interested in...



FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says

The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn

FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says

The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn

NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002

FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002

Related Content

UsernamePublicRestriction

Register

PS037263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel